The slurry technique was employed to produce proniosomes based on maltodextrin, loaded with captopril, using different ratios of surfactant to carrier. The proniosome formulation was evaluated for FT-IR analysis and scanning electron microscopy. The stability, kinetic data analysis, in vitro release testing, and trapping efficacy of the niosomal dispersion were further evaluated. The smooth surface of the proniosome is the result of the scanning electron microscopy (SEM) research. Among the three formulations, formulation F3 demonstrated superior performance with an entrapment efficiency of 95.69% and an in vitro cumulative drug release of 103.16% after 12 hours. The phenomenon of first-order kinetics offered the most comprehensive explanation for the process of release. The medication is released following Fickian release, as determined by kinetic studies. The proteosome formulation exhibited sufficient stability for a duration of 45 days by being stored under different conditions. Captopril is an effective treatment for both congestive heart failure and hypertension. However, in order to meet clinical requirements, it is necessary to take the 50 mg daily dose three times a day. Developing a captopril dosage form with an extended duration of action offers several benefits. Developing sustained-release or controlled-release oral captopril formulations has been a longstanding challenge